Journal
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
Volume 36, Issue 6, Pages 1354-1362Publisher
FIELD HOUSE PUBLISHING LLP
DOI: 10.1177/147323000803600624
Keywords
METOPROLOL; HYPERTENSION; CYP2D6; beta(1) ADRENERGIC RECEPTOR; GENE POLYMORPHISM
Funding
- Ministry of Science and Technology [2005CCA04000]
- Study Foundation of the Committee of the Provincial Science Study Foundation of Hunan, China [06SK2003]
Ask authors/readers for more resources
Metoprolol is a lipophilic beta(1) selective adrenergic receptor antagonist used in antihypertensive therapy. it is metabolized by the protein product of the cytochrome P450 2D6 (CYP2D6) gene. Few studies have been performed on the association between the beta(1) adrenoreceptor, CYP2D6 polymorphism and blood pressure. The one reported here is a prospective, observational, clinical study in Chinese Han hypertensive patients on the combined influences of CYP2D6 and beta(1) adrenoreceptor polymorphisms on the therapeutic effects of metoprolol in 300 out-patients with essential hypertension. The some dose of metoprolol achieved different therapeutic effects in patients with different CYP2D6 and beta(1), adrenoreceptor polymorphisms. Additionally, different doses of metoprolol could achieve the same therapeutic effects in patients with different CYP2D6 and beta(1), adrenoreceptor polymorphisms. Knowledge of the combination of CYP2D6 and beta(1), adrenoreceptor polymorphisms may be used to guide antihypertensive therapy using beta(1), adrenoreceptor antagonists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available